banda transcan 2 2016ul

Title: Biomarkers of tumor recurrence in pancreatic cancer.


Project Coordinator:
Thomas M. GRESS (Germany) Philipps-Universität Marburg, Marburg


Project Partners:
Alfredo CARRATO (Spain ) Ramon y Cajal University Hospital, Madrid
Aldo SCARPA (Italy) Dipartimento ad Attività Integrata (DAI) di Patologia e Diagnostica, Verona
Nathalia GIESE (Germany) Universität Heidelberg, Heidelberg
Núria MALATS (Spain) Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid


Project Abstract:
Pancreatic cancer has the worst prognosis of all solid tumors with 5-year survival rates < 5%. Surgical resection of early stage tumors to date offers the only hope for potentially curative treatment. However, local and/or distant tumor recurrence is a frequent event even after R0 resection, thus current guidelines recommend adjuvant chemotherapy that has been shown to double 5-year-survival rates for these patients (20.7% vs 10.4%). Even so, recurrence is still the most common course of the disease, and no standard means for diagnosis and treatment of early recurrence are established yet. The development of novel approaches for postoperative monitoring of resected patients to detect recurrence at an early time point would thus address an unmet clinical need that would be a key factor in increasing survival and quality of life in these patients. Members of this consortium have previously identified a panel of diagnostic mRNA and miRNA markers and have designed the prototype of a diagnostic tool utilizing the TaqMan Array technology. The aim of this proposal is to i) additionally incorporate detection of pancreatic cancer-associated genomic mutations in the biomarker array, and to ii) validate the pancreatic cancer TaqMan array through different stages of technical and early clinical validation in the setting of PDAC patients resected with curative intent. The final goal is to develop a diagnostic tool to be used during follow-up of resected patients for the early, accurate and non-invasive detection of systemic markers of recurrence at a stage when it is not yet detectable by imaging. To technically validate the biomarker array, we will analyze “liquid biopsies” (serum, urine) of patients from existing collections and case/control studies which are stored in quality assured biobanks in the consortium. In the second stage of the project, the diagnostic performance of the biomarker TaqMan array will be rigorously validated using patient samples prospectively collected within the project at different time points after R0 resection of pancreatic cancer. The consortium comprises clinical partners in leading European centers with extensive experience in the management of pancreatic cancer patients as well as pancreatic cancer molecular biology and biomarker discovery. Moreover, existing collaborations with industrial partners will be instrumental in translating the scientific results into marketable clinical applications.

(Project funded under JTC 2013)


TRANSCAN News

 TRANSCAN-3 news on:
twitter logoinkedin social media logo

TRANSCAN-3   JOINT TRANSNATIONAL CALL 2022 on:
 "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy"  

is open for submission

Please visit the TRANSCAN-3 website at
https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl


Other news:

The Digital Institute for Cancer Outcomes Research (DIGICORE),  is delighted to announce an innovative new training programme for early career researchers in oncology: IDEAL4RWE.
 Please register for an introductory webinar on the19th April 2022(https://lnkd.in/ez7y4kWU).
Brochure for more details: https://tinyurl.com/y7aurdtk


 The first TRANSCAN-3 call (JTC 2021) on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"
is closed for submission

International Networking Event (virtual)
on 22 April 2021 hrs 9:00 CET
will focus on the forthcoming co-funded JTC 2021 on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment" 
the event is organized by TUBITAK under the “Turkey in Horizon 2020 Phase II” Technical Assistance Project
in cooperation with TRANSCAN-3

The new ERA-NET Cofund TRANSCAN-3:
 Sustained collaboration of national and regional programmes in cancer research
is funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download

 

Newsletters

The TRANSCAN-3 newsletters are published at: https://www.transcan.eu/

SUBSCRIBE to the newsletters
You can unsubscribe at any moment by clicking on the subscription preferences link at the bottom of a received newsletter


All the TRANSCAN-2 newsletters:

Newsletter 10, Sept.2020
Newsletter 9, Dec.2019

Newsletter 8, May 2019
Newsletter 7, Oct.2018
Newsletter 6, June 2108
Newsletter 5, March 2018
Newsletter 4, Dec. 2017
Newsletter 3, Sept. 2017
Newsletter 2, April 2017
Newsletter 1, Dec. 2016

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Who's Online

We have 5 guests and no members online